CN117940128A - 异丁司特用于防止眼癌转移 - Google Patents
异丁司特用于防止眼癌转移 Download PDFInfo
- Publication number
- CN117940128A CN117940128A CN202280059689.8A CN202280059689A CN117940128A CN 117940128 A CN117940128 A CN 117940128A CN 202280059689 A CN202280059689 A CN 202280059689A CN 117940128 A CN117940128 A CN 117940128A
- Authority
- CN
- China
- Prior art keywords
- day
- ibudilast
- cancer
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163225820P | 2021-07-26 | 2021-07-26 | |
| US63/225,820 | 2021-07-26 | ||
| PCT/US2022/038157 WO2023009425A1 (en) | 2021-07-26 | 2022-07-25 | Ibudilast for preventing eye cancer metastasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117940128A true CN117940128A (zh) | 2024-04-26 |
Family
ID=82851760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280059689.8A Pending CN117940128A (zh) | 2021-07-26 | 2022-07-25 | 异丁司特用于防止眼癌转移 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12005049B2 (https=) |
| EP (1) | EP4376838A1 (https=) |
| JP (1) | JP2024528731A (https=) |
| CN (1) | CN117940128A (https=) |
| CA (1) | CA3226898A1 (https=) |
| WO (1) | WO2023009425A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12005049B2 (en) | 2021-07-26 | 2024-06-11 | Medicinova, Inc. | Methods of preventing cancer metastasis |
| US12042485B2 (en) | 2021-10-07 | 2024-07-23 | Medicinova, Inc. | Methods of minimizing cancer metastasis |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6395747B1 (en) | 1998-08-10 | 2002-05-28 | Sauro Sakoda | Remedies for multiple sclerosis |
| JP4954085B2 (ja) | 2004-12-06 | 2012-06-13 | メディシノバ， インコーポレイテッド | 神経障害性疼痛及びその関連する症状を治療するためのイブジラスト |
| US8138201B2 (en) | 2007-07-11 | 2012-03-20 | Medicinova, Inc. | Treatment of progressive neurodegenerative disease with ibudilast |
| EP2858635A1 (en) * | 2012-06-11 | 2015-04-15 | The Regents of The University of California | Inhibitors of hippo-yap signaling pathway |
| KR102462638B1 (ko) | 2014-11-26 | 2022-11-03 | 메디시노바, 인크. | 이부딜라스트와 릴루졸의 배합물 및 이의 사용방법 |
| WO2018119262A1 (en) | 2016-12-22 | 2018-06-28 | Medicinova, Inc. | Methods of treating glioblastoma multiforme using ibudilast |
| ES2959799T3 (es) | 2018-02-12 | 2024-02-28 | Medicinova Inc | Métodos para suprimir células supresoras de origen mieloide en pacientes |
| JP2021512921A (ja) | 2018-02-12 | 2021-05-20 | メディシノバ・インコーポレイテッドＭｅｄｉｃｉＮｏｖａ， Ｉｎｃ． | 癌療法に対するイブジラストおよび第二の薬剤を使用した方法ならびに投与レジメン |
| WO2020076809A1 (en) | 2018-10-09 | 2020-04-16 | Medicinova, Inc. | Combination of ibudilast and interferon-beta and methods of using same |
| CN112804999B (zh) | 2018-10-19 | 2024-03-15 | 美迪诺亚公司 | 通过异丁司特治疗眼科疾病/病症或损伤的方法 |
| EP4034090A1 (en) | 2019-09-23 | 2022-08-03 | MediciNova, Inc. | Ibudilast oral formulations and methods of using same |
| CA3174413A1 (en) | 2020-04-06 | 2021-10-14 | Yuichi Iwaki | Methods of reducing plasma level of macrophage migratory inhibitory factor in patients with ibudilast |
| WO2022164948A1 (en) | 2021-01-29 | 2022-08-04 | Medicinova, Inc. | Methods of treating chemical gas exposure |
| US12005049B2 (en) | 2021-07-26 | 2024-06-11 | Medicinova, Inc. | Methods of preventing cancer metastasis |
| CA3231869A1 (en) | 2021-09-21 | 2023-03-30 | Medicinova, Inc. | Ibudilast in combination therapy for use in the treatment of glioblastoma |
| US12042485B2 (en) | 2021-10-07 | 2024-07-23 | Medicinova, Inc. | Methods of minimizing cancer metastasis |
| CN118973574A (zh) | 2022-02-01 | 2024-11-15 | 美迪诺亚公司 | 异丁司特治疗新冠肺炎后遗症的用途 |
-
2022
- 2022-07-25 US US17/872,855 patent/US12005049B2/en active Active
- 2022-07-25 JP JP2024505211A patent/JP2024528731A/ja active Pending
- 2022-07-25 WO PCT/US2022/038157 patent/WO2023009425A1/en not_active Ceased
- 2022-07-25 CA CA3226898A patent/CA3226898A1/en active Pending
- 2022-07-25 EP EP22754252.9A patent/EP4376838A1/en active Pending
- 2022-07-25 CN CN202280059689.8A patent/CN117940128A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12005049B2 (en) | 2024-06-11 |
| CA3226898A1 (en) | 2023-02-02 |
| US20230037014A1 (en) | 2023-02-02 |
| EP4376838A1 (en) | 2024-06-05 |
| JP2024528731A (ja) | 2024-07-30 |
| WO2023009425A1 (en) | 2023-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2913047B1 (en) | Pulmonary disease-specific therapeutic agent | |
| CN101848712B (zh) | 用异丁地特治疗渐进性神经变性疾病 | |
| JP2017509684A5 (https=) | ||
| KR20120131245A (ko) | 기관지 감염의 치료 방법 | |
| JP2025020319A (ja) | テルリプレシン組成物およびその使用方法 | |
| JP6803898B2 (ja) | オメガ−３脂肪酸およびトマトリコペンを含む抗炎症性相乗的組み合わせ | |
| JP2017534604A5 (https=) | ||
| CN117940128A (zh) | 异丁司特用于防止眼癌转移 | |
| KR20170095807A (ko) | 폐 고혈압의 치료를 위한 흡입가능 라파마이신 제제 | |
| CN112236140A (zh) | 用于癌症治疗的使用异丁司特和第二药剂的方法和剂量方案 | |
| US20250228779A1 (en) | Method and composition for treating pulmonary fibrosis | |
| KR102375232B1 (ko) | 비강내 에피네프린 제제 및 질환의 치료 방법 | |
| US20210177812A1 (en) | Methods of suppressing myeloid-derived suppressor cells in patients | |
| CN118139619A (zh) | 异丁司特以联合治疗方式用于治疗胶质母细胞瘤 | |
| US12042485B2 (en) | Methods of minimizing cancer metastasis | |
| JP2021502337A (ja) | 関節内適用のための持続放出製剤 | |
| CN112770748A (zh) | 异丁司特和干扰素-β的组合及其使用方法 | |
| KR20210131996A (ko) | 과다복용 및 보상-기반 장애의 치료를 위한 조성물, 장치 및 방법 | |
| US20230029336A1 (en) | Combination Therapy for Treating a Hematological Malignancy | |
| US20050244335A1 (en) | Methods and compositions related to increasing antitumor activity of chemotherapeutic agents | |
| HK40014065A (en) | Terlipressin composition for use in treating ascites | |
| HK40014065B (en) | Terlipressin composition for use in treating ascites | |
| HK1147953A (en) | Treatment of progressive neurodegenerative disease with ibudilast |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |